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A B S T R A C T
Objective: To analyse trends in antibiotic use in Dutch 
hospitals over the period 1997 to 2002.  
Methods: Data on the use of antibiotics and hospital 
resource indicators were obtained by distributing a question-
naire to all Dutch hospital pharmacies. Antibiotic use was 
expressed as the number of defined daily doses (DDD) per 
100 patient-days and as DDD per 100 admissions. 
Results: Between 1997 and 2002, the mean length of 
stay decreased by 18%. The mean number of admissions 
remained almost constant. Total antibiotic use significantly 
increased by 24%, from 47.2 in 1997 to 58.5 DDD per 100 
patient-days in 2002 (p<0.001), whereas expressed as 
DDD per 100 admissions it remained constant. Antibiotic 
use varied greatly between the hospitals. Moreover, the 
mean number of DDD per hospital of amoxicillin with 
clavulanic acid, clarithromycin, cefazolin, clindamycin 
and ciprofloxacin increased by 16, 38, 39, 50 and 52%, 
respectively. Total antibiotic use was higher in university 
hospitals than in general hospitals.  
Conclusion: Between 1997 and 2002, patients hospital-
ised in the Netherlands did not receive more antibiotics 
but, since they remained in the hospital for fewer days, 
the number of DDD per 100 patient-days increased. For 
macrolides, lincosamides and fluoroquinolones increases 
in both DDD per 100 patient-days and in DDD per 100 
admissions were observed. It is arguable whether these 
trends result in an increase in selection pressure towards 
resistance in the hospitals. Continuous surveillance of 
antibiotic use and resistance is warranted to maintain 
efficacy and safety of antibiotic treatment. 
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I N T R O D U C T I O N
The increasing prevalence of antibiotic resistant micro-
organisms poses a major threat to the health of hospital-
ised patients.1,2 Its relationship with antibiotic use and 
misuse is well recognised. Specific criteria for appropri-
ate use of antibiotics in order to avoid resistance should 
therefore be developed.3 Quantitative and qualitative data 
on the use of antibiotics in hospitals are needed to evalu-
ate strategies that are implemented to contain antimicro-
bial resistance. Obviously, resistance rates also need to be 
measured. 
In Sweden, Denmark and the Netherlands, annual 
reports are issued in which resistance rates and antibiotic 
use data are reported.4-6 In the Netherlands, Janknegt 
et al. collected data on the use of antibiotics in Dutch 
hospitals during the period 1991 to 1996.7 In 1996 the 
Working Party on Antibiotic Policy (acronym is SWAB; 
www.swab.nl) was founded by the Dutch Society for 
Medical Microbiology (NVMM), the Society for Infectious 
Diseases (VIZ) and the Dutch Association of Hospital 
Pharmacists (NVZA). The main activities of SWAB are 
development of guidelines and educational programmes 
to promote appropriate use of antibiotics and the surveil-
lance of antibiotic use and resistance. These activities are 
supported by a structural grant from the Dutch Ministry 
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of Health, Welfare and Sport. In 2000 SWAB’s working 
group on the use of antimicrobial agents started to collect 
national data on antibiotic use in hospitals. These data are 
presented in NethMap, the annual report of the SWAB.6
In a recent editorial in this journal it was stated that 
physicians would not directly benefit from these national 
reports in their daily practice, but that these reports may 
help to increase their general awareness of the problem 
of antibiotic resistance.8 Furthermore these reports may 
provide a knowledge base for policy decisions, guidelines 
and research strategies.
The aim of this study was therefore to analyse and report on 
antibiotic use in Dutch hospitals between 1997 and 2002. 
M A T E R I A L S  A N D  M E T H O D S
Population
All Dutch hospitals, 94 general hospitals and 8 university 
hospitals, were asked to participate in SWAB’s national 
surveillance system. Specialised hospitals, such as psychia-
tric and orthopaedic hospitals, and rehabilitation centres 
were excluded. Data on the use of antibiotics in acute care 
Dutch hospitals between 1997 and 2002 were collected by 
means of a questionnaire distributed to all Dutch hospital 
pharmacies by SWAB. Data from inpatient wards as well 
as day care wards had to be included, whereas outpatient 
use and dispensing to nursing homes was excluded from 
the data report.
Antibiotic use
Pharmacies were requested to report on the annual con-
sumption of antibiotics for systemic use, group J01 of the 
Anatomical Chemical Classification (ATC) system. The 
use of different (sub)classes of antibiotics was expressed 
as defined daily doses (DDD) per 100 patient-days and 
per 100 admissions.9
The ATC/DDD classification from the World Health 
Organisation (WHO), version 2002, was used to calcu-
late the number of DDD of the various antibiotics. The 
DDD was defined as the assumed average maintenance 
dose per day for a drug used for its main indication in an 
adult.10
Hospital resource data
For each hospital the annual number of admissions and 
days spent in the hospital (bed-days) were recorded. The 
number of patient-days was obtained by subtracting the 
number of admissions from the number of bed-days as 
the number of bed-days overestimates actual treatment-
days by including both the day of admission and the day 
of discharge. The mean length of stay was calculated by 
dividing the mean number of patient-days by the mean 
number of admissions.
 
Statistical analysis
Regarding the period 1997 to 2002 an overall pooled 
mean (i.e. weighted mean) was calculated for each year by 
aggregating data on antibiotic use and patient-days from 
all the hospitals. Drug utilisation was compared between 
hospitals and over time by a mixed model for repeated 
measurements. The response variables applied were the 
number of DDD per 100 patient-days and the number 
of DDD per 100 admissions. P values less than 5% were 
considered statistically significant. All statistical analyses 
were performed by SAS 8.2 (SAS Institute, N.C., USA).
R E S U LT S
Hospital resource indicators
Between 1997 and 2002 a decrease in the mean length 
of stay was found in both the total cohort of hospitals and 
the subgroups of university and general hospitals (table 1). 
The mean number of admissions remained almost con-
stant. As the mean number of patient-days is calculated 
by multiplying the mean number of admissions by the 
mean length of stay, a decrease was also found in the 
mean number of patient-days. 
Hospital use
The number of hospitals that issued data on antibiotic 
use varied from 49 (48%) in 1997 to 59 (58%) in 2002. 
The reasons given for not participating were other prior-
ities (56%), not being able to generate data on antibiotic 
use (25%) or no interest (19%). 
In 1997 total systemic use in hospitals was 47.2 DDD per 
100 patient-days and significantly increased by 24% to 58.5 
DDD per 100 patient-days in 2002 (p<0.001) (table 2). 
However, total systemic use expressed as DDD per 100 
admissions remained almost constant at 385.9 in 1997 
and 391.6 in 2002 (p=0.866) (table 3).
The mean number of total DDD per hospital did not 
change between 1997 and 2002 (67,176 and 66,714 DDD 
in 1997 and 2002, respectively). 
Regarding trends in antibiotic use over the years, five 
main categories can be distinguished:
• For macrolides, lincosamides and fluoroquinolones 
we found a significant increase over the years for both 
units of measurement; 
• For amphenicols and monobactams a significant 
decrease in both units of measurement was found; 
• For tetracyclines, -lactamase-resistant penicillins, 
carbapenems, trimethoprim and derivatives, inter-
mediate-acting sulfonamides, aminoglycosides and 
imidazole derivatives, a constant use in both units of 
measurement was found;
• For total systemic use, combinations of penicillins 
including -lactamase inhibitors, -lactamase-sensitive 
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penicillins, cephalosporins and glycopeptides, a signifi-
cant increase in DDD per 100 patient-days and a con-
stant use in DDD per 100 admissions was observed; 
• For penicillins with extended spectrum and combina-
tions of sulfonamides and trimethoprim we found a 
constant use when expressed in DDD per 100 patient-
days; a significant decrease in the number of DDD per 
100 admissions was also found.
The proportion of all penicillins combined represented 
55% of total systemic use in both 1997 and 2002. In an 
in-depth study of the individual antibiotics we found that 
the mean number of DDD per hospital of amoxicillin with 
clavulanic acid, clarithromycin, cefazolin, clindamycin 
and ciprofloxacin increased by 16, 38, 39, 50 and 52%, 
respectively.
In university hospitals, total systemic antibiotic use 
increased significantly by 16.5%, from 57.6 in 1997 to 67.1 
DDD per 100 patient-days in 2002 (p=0.002), whereas 
in general hospitals total use increased significantly 
by 29.4%, from 43.6 in 1997 to 56.4 DDD per 100 
patient-days in 2002 (p<0.001). However, total systemic 
antibiotic use expressed as DDD per 100 admissions in 
university hospitals remained almost constant at 507.4 in 
1997 and 525.2 in 2002. In general hospitals no increase 
was found either when use was expressed as DDD per 
100 admissions: 347.4 in 1997 and 364.2 in 2002. In 
university hospitals the mean number of DDD per hos-
pital decreased by 1.5%, whereas in general hospitals an 
increase of 6.5% was observed.
Moreover, a large variation in quantitative antibiotic use 
was found between the participating hospitals, in particu-
lar in general hospitals (figure 1).
D I S C U S S I O N
Our data showed a decrease in the mean length of stay 
during the study period and a more or less constant 
mean number of admissions. These trends in hospital 
resource indicators are consistent with the demographics 
of all the hospitals as registered by Statistics Netherlands 
(www.cbs.nl). In addition, we found that trends over time 
in DDD per 100 patient-days did not consistently correlate 
with trends in DDD per 100 admissions. 
In the present study total antibiotic use significantly 
increased by 24%, from 47.2 in 1997 to 58.5 DDD per 
100 patient-days in 2002. The total number of DDD and 
admissions remained almost constant between 1997 and 
2002. However, length of stay decreased significantly 
during this period. This means that on average patients 
used the same number of DDD in a shorter period of 
time, which might be interpreted in different ways. 
Firstly, no changes in treatment policies occurred since 
most patients were already treated with antibiotics during 
the first days of hospitalisation. Due to intensification of 
general care, the length of stay decreased. Another explan-
ation might be that antibiotic courses are completed at 
home with antibiotics supplied by the hospital. 
Between 1991 and 1996 total antibiotic use in Dutch hos-
pitals increased by 14% from 37.2 to 42.5 DDD per 100 
patient-days in 1996.7 This might also be the result of a 
decreasing length of stay over the years (12%) rather than 
an increase in DDD per admission. The first results of a 
European surveillance programme demonstrated that the 
Nordic countries and the Netherlands all show a low total 
antibiotic use compared with other European countries.11 
In both university and general hospitals we found a con-
stant use in DDD per 100 admissions and an increase 
in DDD per 100 patient-days as well. Total systemic 
antibiotic use was notably higher in university hospitals 
than in general hospitals. This might be explained by the 
admission of patients with more complex infections or 
undergoing complex surgery and transplantations requir-
ing prophylaxis. 
In the total cohort of hospitals the mean number of DDD 
per hospital of amoxicillin with clavulanic acid, clarithro-
mycin, cefazolin, clindamycin and ciprofloxacin increased 
with 16, 38, 39, 50 and 52%, respectively. As the number 
of admissions remained almost constant over the years 
this means an increase in the consumption of these anti-
biotics per admission. The increase in the use of cefazo-
lin, an agent that is only used for perioperative prophy-
laxis, may be explained by the publication of a national 
guideline on perioperative antibiotic prophylaxis in 2000. 
This guideline strongly recommends the use of cefazo-
lin for surgical prophylaxis.12 In our cohort of hospitals 
the percentage of hospitals using cefazolin increased 
from 37% in 1997 to 69% in 2002 (p=0.001). It is not 
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clear why the use of the other antibiotics is increasing. 
Audits on antibiotic prescribing practices at the individual 
patient level are needed to clarify the increasing use of 
these antibiotics. 
We distinguished five categories concerning trends in 
antibiotic use over the years. With regard to resistance 
development it appears that an increase in both the 
number of DDD per 100 patient-days and the number 
of DDD per 100 admissions (category 1) is a cause for 
concern and that no significant change or a significant 
decrease in both units of measurement (category 2, 3 and 
5) is not. The trend in category 4 is less easy to interpret. 
An increase in the number of DDD per 100 patient-days 
may be interpreted as an increase in the selection pres-
sure towards resistance. However, this is arguable since 
the number of admissions and the total number of DDD 
has remained almost constant over the years. Moreover, 
an intensification of antibiotic therapy suggests a shorten-
ing of duration of antibiotic treatment. Short duration of 
therapy may lead to less selection of resistant microorgan-
isms.13,14
In the present study some methodological problems were 
encountered. Firstly, one possible source of bias was the 
variety of methods used by the different Dutch hospital 
pharmacies to quantify their antibiotic use. The majority 
of hospitals delivered data based on hospital purchases, 
while only a few hospitals provided actual dispensing 
data. Ideally, actual administration data should be used as 
a source to measure antibiotic use in hospitals, with every 
dose actually administered to a patient recorded electron-
ically. 
Secondly, we aimed to provide census data, covering at 
least 90% of the acute care hospital population in the 
Netherlands. The overall response to the enquiry was, 
however, 58%. In contrast with Denmark, for example, 
the Dutch government does not make it compulsory for 
hospitals to deliver their data on the use of antibiotics.15 
Consequently aiming at 90% coverage will be unrealistic. 
Since the variance in antibiotic use is very large between 
the hospitals, a representative selection of hospitals is 
only possible when insight is obtained in the determinants 
of hospital antibiotic use.
Another possible source of bias may be that as a result 
of earlier discharge of the less ill patients, patient-days 
may increasingly originate from sicker patients who more 
often require antibiotic treatment. However, this is not 
likely, as the total number of DDD remained constant. 
In this survey, data were collected by a questionnaire and 
processed manually, which is a relatively slow process. 
In the near future the SWAB wishes to start a national 
project in order to collect data on hospital drug use in a 
central data warehouse. This will facilitate the collection 
of data and the conversion to DDD per 100 patient-days.
Data on the use of antibiotics at hospital level might be 
too crude for identifying subtle trends in antibiotic use 
of specific patient populations. Therefore, monitoring 
antibiotic use patterns by specific populations within the 
hospital (e.g. intensive care and general ward patients; 
surgical and nonsurgical patients) is warranted. In this 
way substantial changes can be demonstrated that would 
be overlooked if hospital-wide data are aggregated into 
national trends.
In conclusion, patients hospitalised in the Netherlands 
did not receive more antibiotics but, since they remained 
in the hospital for fewer days, the number of DDD per 
100 patient-days increased. It is arguable whether this 
results in an increase in selection pressure towards resist-
ance in the hospitals, since the total number of DDD 
remained almost constant over the years. For macrolides, 
lincosamides and fluoroquinolones increases in both 
DDD per 100 patient-days and DDD per 100 admissions 
were observed between 1997 and 2002. This might be 
a cause for concern since this trend is more likely to be 
associated with an increase in the selection pressure. 
Further research is needed to determine the relationship 
between antibiotic use, selection pressure and the emer-
gence of resistance. To maintain efficacy and safety of 
antibiotic treatment, continuous surveillance of antibiotic 
use and resistance is necessary. 
A C K N O W L E D G E M E N T
We thank the pharmacists of the participating hospitals for 
providing data on antibiotic use. This study was supported 
with a structural grant from the Ministry of Health, Welfare 
and Sport to the SWAB, no. 366950.01.
R E F E R E N C E S
1. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial 
treatment of infections: a risk factor for hospital mortality among critically ill 
patients. Chest 1999;115:462-74.
2. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic 
outcomes of the emergence of third-generation cephalosporin resistance 
in Enterobacter species. Arch Intern Med 2002;162:185-90.
3. Gyssens IC. Quality measures of antimicrobial drug use. Int J Antimicrob 
Agents 2001;17:9-19.
4. SWEDRES 2004. A report on Swedish Antibiotic Utilisation and 
Resistance in Human Medicine. ISSN 1400-3473. Swedish Strategic 
Programme for the Rational Use of Antimicrobial Agents (STRAMA) 
and the Swedish Institute for Infectious Disease Control. Sweden, Solna, 
2004.
5. DANMAP 2003. Use of Antimicrobial Agents and Occurence of 
Antimicrobial Resistance in Bacteria from Food Animals, Foods and 
Humans in Denmark. ISSN 1600-2032. Danish Vetrinary Institute. 
Denmark, Copenhagen, 2003.
O C T O B E R  2 0 0 5 ,  V O L .  6 3 ,  N O .  9
359
6. SWAB. NethMap 2005 - Consumption of antimicrobial agents and  
antimicrobial resistance among medically important bacteria in  
the Netherlands [On-line]. Cited 20 June 2005. http://www.swab.nl. 
7. Janknegt R, Oude Lashof A, Gould IM, Van der Meer JWM. Antibiotic use 
in Dutch hospitals 1991-1996. J Antimicrob Chemother 2000;45:251-6.
8. Cars O. Annual reports of antibiotic use and resistance – for whom? 
Neth J Med 2004;62:405-6.
9. Filius PMG, Liem TBY, Van der Linden PD, Janknegt R, Natsch S, Vulto AG, 
Verbrugh HA. An additional measure for quantifying antibiotic use in 
hospitals. J Antimicrob Chemother 2005;55:805-8.
10. WHO Collaborating Centre for Drug Statistics Methodology. ATC index 
with DDDs 2002. WHO Collaborating Centre; Oslo, Norway. 2001.
11. Elseviers M, Ferech M, Vander Stichele R, editors. Consumption of 
antibiotics in hospital care in Europe: first results of the ESAC retro-
spective data collection [abstract]. 13th European Congress of Clinical 
Microbiology and Infectious Diseases; Glasgow, UK. 2003. 
Liem, et al. Changes in antibiotic use in Dutch hospitals.
12. Kasteren MEE van, Gyssens IC, Kullberg BJ et al. Optimising antibiotics 
policy in the Netherlands. V. SWAB guidelines for perioperative prophy-
laxis. Ned Tijdschr Geneeskd 2000;144(43):2049-55.
13. Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose 
amoxicillin therapy on resistant pneumococcal carriage: a randomized 
trial. JAMA 2001;286:49-56.
14. Meer JW van der, Natsch S. Completing a course of drug therapy 
is necessary to combat the infection, not to discourage emergence of 
resistance. Ned Tijdschr Geneeskd 2004;148(35):1720:2.
15. Müller-Pebody B, Muscat M, Pelle B, Klein BM, Brandt CT, Monnet DL. 
Increase and change in pattern of hospital antimicrobial use, Denmark, 
1997-2001. J Antimicrob Chemother 2004;54:1122-6.
O C T O B E R  2 0 0 5 ,  V O L .  6 3 ,  N O .  9
360
‘Untitled’
Jochen Proehl
A B O U T  T H E  C O V E R
This print is a brush technique on hand-
made paper by Jochen Proehl. 
Born in Lübeck, Germany, in 1958, Jochen 
Proehl was raised in Istanbul. From 1982 
to 1988 he attended the Academy of Arts 
in Berlin. After graduation, he has received 
many assignments for different institutions. 
He exhibits his work in many group and 
solo exhibitions in Germany. Proehl alternates where he lives 
and works between Berlin, am Niederrhein and Istanbul. 
Inconspicuous views of shapes that materialise when 
man encroaches upon territories, such as holes, pits 
or puddles, are the catalysts for Jochen 
Proehl’s etchings. These unspectacular 
traces of human intervention appear in 
his pictures as escapist scenery clippings 
and – characteristic for his work – as an 
elementary concept of power and tran-
quillity.
An original print, size 40.5 x 30.5 cm, is 
available at a price of € 160 and can be ordered from Galerie 
Unita, Rijksstraatweg 109, 6573 CK Beek-Ubbergen,  
the Netherlands or by e-mail: Galerie-unita@planet.nl or 
www.galerie-unita.com.
